Chardan Capital Reaffirms Buy Rating for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a research report issued on Friday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock. Chardan Capital’s target price would indicate a potential upside of 332.43% from the stock’s previous close.

A number of other research firms also recently commented on IOVA. Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective on the stock in a report on Tuesday, March 3rd. Wall Street Zen upgraded Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. UBS Group raised their target price on Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a report on Thursday, March 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday, April 6th. Finally, The Goldman Sachs Group reiterated a “sell” rating and set a $2.00 target price on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.88.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock opened at $3.70 on Friday. The stock’s 50-day moving average is $3.49 and its 200-day moving average is $2.76. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -3.30 and a beta of 0.76. Iovance Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $5.63.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The company had revenue of $86.77 million for the quarter, compared to the consensus estimate of $81.61 million. Iovance Biotherapeutics had a negative return on equity of 54.54% and a negative net margin of 148.41%. Research analysts anticipate that Iovance Biotherapeutics will post -1.24 EPS for the current year.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Iovance Biotherapeutics by 13.1% during the 4th quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock valued at $74,275,000 after purchasing an additional 3,148,096 shares in the last quarter. State Street Corp grew its stake in Iovance Biotherapeutics by 51.5% during the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock valued at $55,041,000 after purchasing an additional 6,851,486 shares in the last quarter. Invenomic Capital Management LP grew its stake in Iovance Biotherapeutics by 13.5% during the 4th quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock valued at $32,649,000 after purchasing an additional 1,417,897 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Iovance Biotherapeutics by 30.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company’s stock valued at $23,499,000 after purchasing an additional 2,032,062 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Iovance Biotherapeutics by 16.4% during the 4th quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company’s stock valued at $21,821,000 after purchasing an additional 1,123,337 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating and set a $16.00 price target (≈332% upside vs. the current price), a high-profile bullish endorsement that can attract longer-term investor interest. Article Title
• Positive Sentiment: Unusually large call-option activity: traders bought about 23,006 call options on Friday (≈213% above average), signaling speculative bullish positioning and potential dealer hedging flows that can amplify intraday moves.
• Positive Sentiment: Positive media/retail attention — The Motley Fool ran a bullish feature highlighting Iovance as a high-upside oncology name, which can drive retail interest and momentum buying. Article Title
• Positive Sentiment: Zacks Research nudged several near-term and FY EPS estimates slightly higher (Q1 2026, Q2 2027, Q1 2028 and FY2028), which improves the analyst tone even though estimates remain negative. Article Title
• Negative Sentiment: Fundamentals still weigh on valuation — consensus full‑year EPS remains negative (around -$1.24) and the company reported negative margins, limiting near-term valuation support and making the stock sensitive to risk-off moves and profit-taking. Article Title

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.